Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HT-1 is a humanized monoclonal antibody developed by HTIC, Inc as a treatment for Acute Respiratory Distress Syndrome (ARDS) Due to an Infectious Source”In the company’s words, NCT07449572 on ClinicalTrials.gov
- Main trialPhase 1
- “This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress syndrome (ARDS) due to an infectious source. The current trial (Part A) focuses on single ascending doses (SAD) in healthy volunteers to characterize the safety profile, PK parameters, and immunogenicity of HT31-1. Emerging data from this phase will inform dose selection for the subsequent Part B study in ARDS patients and help establish the recommended Phase 2 dose…”In the company’s words, NCT07449572 on ClinicalTrials.gov
Other drugs for ARDS (Acute Respiratory Distress Syndrome)
- ParidiprubartPPD Development, LP · Phase 2
- VilobelimabInflaRx GmbH · Phase 2
- GKL-006AlloBeijing Gene Key Life Technology Co., Ltd · Phase 1/2
- AtibuclimabImplicit Bioscience · Phase 2
Coming up1
- Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jan 2027 | Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026